1. Home
  2. News
  3. Zelira Therapeutics Ltd.
  4. Zelira receives $1.2 million cash R&D Tax Incentive
More Zelira Therapeutics Ltd. news
Zelira Therapeutics Ltd.ASX: ZLD

Zelira receives $1.2 million cash R&D Tax Incentive

Jan 11, 2022 at 10:42 PM EST · Issued by Zelira Therapeutics Ltd.

Filed with ASX · Jan 11, 2022 at 10:42 PM EST · 2 pages · English

On 6ix: 6ix.com/news/zelira-receives-dollar1.2-million-cash-randd-tax-incentive

Zelira Therapeutics Ltd. on 6ix

In the deck

  • Zelira Therapeutics — Shareholder Meeting (January 2022)22 slidesJan 13, 2022

Story so far

  • R&D Tax Incentive RefundDec 11, 2020

Earlier from Zelira Therapeutics

  • Partial Receipt Of Zeliras EDCDM Technology License FeeJan 9, 2022
  • Zelira expands into NZ via exclusive distribution agreementDec 15, 2021
  • ZLD Supports Levins Chronic Pain Trial Ethics ApprovalDec 1, 2021
  • Zelira Develops Technology and Signs New Licensing DealNov 2, 2021
  • September 2021 Quarterly Activities ReportOct 28, 2021

Later from Zelira Therapeutics

  • December 2021 Quarterly Activities ReportJan 30, 2022
  • Appendix 4D & FY22 Interim Financial ReportFeb 23, 2022
  • Zelira Therapeutics Ltd to acquire Health HouseFeb 23, 2022
  • ZLD: Zelira to acquire Health House International LimitedFeb 23, 2022
  • March 2022 Quarterly Activities ReportApr 28, 2022
All Zelira Therapeutics news releases↗

Follow Zelira Therapeutics into a list and get an email when it puts out news.

Follow Zelira Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer